Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chloramphenicol: recent developments and clinical indications.

M I Marks, C Laferriere

    Clinical Pharmacy
    |July 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococcal central-line-associated bloodstream infections in a neonatal intensive care unit.

    The Journal of antimicrobial chemotherapy·2017
    Same author

    Oral therapy for orthopedic infections in children and adults.

    Orthopedics·2014
    Same author

    Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections.

    The Pediatric infectious disease journal·2013
    Same author

    URIs in children.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    Smallpox vaccination.

    Canadian Medical Association journal·2010
    Same author

    Adverse reactions to 1975 bivalent influenza vaccine in children.

    Canadian Medical Association journal·2010
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    Revised chloramphenicol guidelines emphasize oral administration (75 mg/kg/day) and serum monitoring to balance efficacy and toxicity. Its use is narrowing due to safer alternatives, particularly for Haemophilus influenzae and anaerobic infections.

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Therapeutics

    Background:

    • Recent advancements in diagnostic assays necessitate updated chloramphenicol usage recommendations.
    • Chloramphenicol's bioavailability and therapeutic dosing require careful consideration for optimal patient outcomes.

    Purpose of the Study:

    • To review revised recommendations for chloramphenicol's route of administration, dosage, and clinical indications.
    • To evaluate the evolving role of chloramphenicol in light of new therapeutic options and safety concerns.

    Main Methods:

    • Review of recent developments and updated clinical guidelines for chloramphenicol.
    • Analysis of pharmacokinetic data regarding oral bioavailability and serum concentration monitoring.
    • Evaluation of specific clinical indications including Haemophilus influenzae infections, anaerobic infections, salmonellosis, Rocky Mountain spotted fever, and ocular infections.

    Related Experiment Videos

    Main Results:

    • Oral administration of chloramphenicol at 75 mg/kg/day generally achieves adequate therapeutic concentrations.
    • Serum concentration monitoring is crucial, especially in neonates, patients with liver dysfunction, or those on interacting medications.
    • Chloramphenicol remains valuable for specific ampicillin-resistant Haemophilus influenzae infections, certain anaerobic and ocular infections, and rickettsioses in children under eight.

    Conclusions:

    • The clinical utility of chloramphenicol is contracting due to the availability of third-generation cephalosporins and other agents like metronidazole and clindamycin.
    • Despite revised guidelines, the persistent risk of aplastic anemia necessitates judicious use of chloramphenicol, reserving it for situations where benefits outweigh risks.